ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,900.72
      0.01%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Ultragenyx Pharmaceutical Inc (RARE)

      7. Ultragenyx Pharmaceutical Inc (RARE) News

      RARE

      Ultragenyx Pharmaceutical (RARE)

      Ultragenyx Pharmaceutical Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:RARE
      DateTimeSourceHeadlineSymbolCompany
      05/02/20244:00PMGlobeNewswire Inc.Ultragenyx Reports First Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
      04/30/20244:00PMGlobeNewswire Inc.Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
      04/30/20248:00AMGlobeNewswire Inc.Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)NASDAQ:RAREUltragenyx Pharmaceutical Inc
      04/25/20244:30PMGlobeNewswire Inc.Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
      04/19/20244:30PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
      04/15/20247:00AMGlobeNewswire Inc.Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102NASDAQ:RAREUltragenyx Pharmaceutical Inc
      04/12/20244:22PMGlobeNewswire Inc.Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman SyndromeNASDAQ:RAREUltragenyx Pharmaceutical Inc
      04/12/20248:00AMGlobeNewswire Inc.Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:RAREUltragenyx Pharmaceutical Inc
      03/22/20244:00PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
      03/05/20248:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
      03/05/20248:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
      03/05/20248:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
      03/05/20248:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
      03/05/20248:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
      03/05/20248:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
      03/05/20248:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
      02/27/20244:30PMGlobeNewswire Inc.Ultragenyx to Participate at Investor Conferences in MarchNASDAQ:RAREUltragenyx Pharmaceutical Inc
      02/23/20244:05PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
      02/21/20245:03PMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RAREUltragenyx Pharmaceutical Inc
      02/15/20244:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
      02/15/20244:01PMGlobeNewswire Inc.Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
      02/08/20244:00PMGlobeNewswire Inc.Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
      02/06/20248:00AMGlobeNewswire Inc.Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)NASDAQ:RAREUltragenyx Pharmaceutical Inc
      02/05/20244:05PMGlobeNewswire Inc.Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman SyndromeNASDAQ:RAREUltragenyx Pharmaceutical Inc
      01/25/20244:05PMGlobeNewswire Inc.Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
      01/19/20244:00PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
      01/08/20247:00AMGlobeNewswire Inc.Mereo BioPharma Provides Update on Pipeline Progress and Corporate DevelopmentsNASDAQ:RAREUltragenyx Pharmaceutical Inc
      01/08/20246:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
      01/07/202411:00AMGlobeNewswire Inc.Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 MilestonesNASDAQ:RAREUltragenyx Pharmaceutical Inc
      01/04/20248:00AMGlobeNewswire Inc.Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)NASDAQ:RAREUltragenyx Pharmaceutical Inc
       Showing the most relevant articles for your search:NASDAQ:RARE